Early Intravenous Immunoglobulin as an Effective Drug for the Treatment of COVID-19: A Case Series and Case Review
| Author | Rozita Khodashahi | en |
| Author | Alireza Sedaghat | en |
| Author | Mandana Khodashahi | en |
| Orcid | Rozita Khodashahi [0000-0002-5360-7426] | en |
| Orcid | Alireza Sedaghat [0000-0001-8927-6545] | en |
| Orcid | Mandana Khodashahi [0000-0003-1198-1783] | en |
| Issued Date | 2020-10-31 | en |
| Abstract | Introduction: The outbreak of coronavirus disease 2019 (COVID-19) should be considered a serious threat to global public health. Due to a large number of infected and dead people, the development of approaches to control the epidemic condition, as well as effective and available drugs, is very important. Case Presentation: In this study, we presented three cases with COVID-19 admitted to the Imam Reza Hospital. A high dose of intravenous immunoglobulin (IVIG) was used for patients as potent and safe treatment. Moreover, case reports and case series focusing on the patients with COVID-19 were reviewed in the present study. During the literature search, 27 patients with COVID-19 were identified in 14 studies. Fever, sore throat, dry cough, fatigue, chills, and muscle pain were the common primary complications of the patients. Kaletra, oseltamivir, ceftriaxone, hydroxychloroquine, azithromycin, and IVIG were the most prevalent drugs for the treatment of COVID-19. Conclusions: Except for the current study, IVIG was utilized in two other studies to treat patients with COVID-19, who did not respond to other therapies. | en |
| DOI | https://doi.org/10.5812/archcid.103732 | en |
| Keyword | Antiviral | en |
| Keyword | COVID-19 | en |
| Keyword | Hydroxychloroquine | en |
| Keyword | Intravenous Immunoglobulin | en |
| Publisher | Brieflands | en |
| Title | Early Intravenous Immunoglobulin as an Effective Drug for the Treatment of COVID-19: A Case Series and Case Review | en |
| Type | Case Report | en |